GULF PHARMACEUTICAL INDUSTRIES JULPHAR CO ADX:JULPHAR:
JULPHAR Q1 ATTRIBUTABLE PROFIT 35 MILLION DIRHAMS
JULPHAR Q1 NET SALES 273.4 MILLION DIRHAMS
JULPHAR - WORKING ON DIVERSIFYING SUPPLY CHAINS WHILE CONTINUING TO MONITOR ENERGY PRICES AND THEIR IMPACT ON OUR ACTIVITIES
JULPHAR -WILL CONTINUE TO ENHANCE ITS FOOTPRINT IN CORE THERAPEUTIC SEGMENTS, DELIVERING ROBUST PERFORMANCE ACROSS UAE, KSA, IRAQ, AND MOROССО
JULPHAR -PLANS EXPANDING MARKET SHARE IN STRATEGIC MARKETS
JULPHAR -PLANS INVESTMENT IN NEW PHARMA AND BIOTECH MANUFACTURING FACILITY IN SAUDI ARABIA
JULPHAR -PLANS TO ACCELERATE IN-HOUSE RD EFFORTS AND FOSTERING STRATEGIC ALLIANCES TO ENHANCE PRODUCT PORTFOLIO
JULPHAR -PLANS TO LAUNCH NEW PRODUCTS IN CORE THERAPEUTIC AREAS
JULPHAR -DURING PERIOD ENDED 31 MARCH 2026, INVESTED AN AMOUNT OF AED 8.2 MILLION IN CAPITAL EXPENDITURES